2019 American Transplant Congress
Donor Hepatitis C Seropositivity Confers Poorer Post-transplant Outcomes In Recipients Of Marginal Livers In The Post-hepatitis C Treatment Era
University of Kentucky, Lexington, KY
*Purpose: Since the introduction of newer antiretroviral therapies, utilization of hepatitis C (HCV) positive livers has increased significantly for HCV recipients. In an effort to…2019 American Transplant Congress
Utilization of Hepatitis C Donors is Safe and Cost Effective
*Purpose: The use of hepatitis C (hep C) positive donors has become increasingly attractive with the advent of improved curative pharmacologic treatments. As a result…2019 American Transplant Congress
Economic Impact of Donor Hepatitis C Kidney Transplantation: A Medicare Cost Analysis
*Purpose: In the era of highly effective direct-acting antiviral agents (DAAs), kidney transplant (KT) from Hepatitis C virus (HCV)-positive donors is increasingly considered as an…2019 American Transplant Congress
Analysis Of Public Health Service Increased Risk Donors Shows No Viral Transmission In Liver Transplant Recipients And Similar Graft / Patient Survival When Compared To Non-increased Risk Donors
Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA
*Purpose: Public Health Service increased risk donors (PHS-IRD) are underutilized in liver transplant (LT) due to concern for transmission of viral (HBV, HCV, and HIV)…2019 American Transplant Congress
Consideration for Offering Hepatitis C Antibody Positive Donor Grafts to All Patients Listed for Transplant
Vanderbilt Transplant Center, Nashville, TN
*Purpose: Background: The field of organ transplantation continuously struggles with inadequate numbers of donor organs. Therefore, efforts remain focused on increasing organ utilization and expanding…2019 American Transplant Congress
Characterization Of Increased Risk Donor Post-transplant Viral Surveillance Protocol At A Comprehensive Transplant Center
University of Virginia Health System, Charlottesville, VA
*Purpose: With the growing opioid crisis, the number of deceased donors classified as Increased Risk Donor (IRD) has increased to nearly 20% nationally. The Organ…2019 American Transplant Congress
Optimal Timing of Hepatitis C Treatment among HIV/HCV Co-Infected End-Stage Renal Disease Patients: Pre vs. Post-Transplant
*Purpose: End-stage renal disease (ESRD) patients co-infected with HCV and HIV have access to effective treatment options for HCV infection. However, they also have access…2019 American Transplant Congress
Hepatitis C Antibody Positive (HCV Ab+)/Nucleic Acid Test Negative (NAT -) Deceased Donor Kidney Transplantation into Hepatitis C Negative (HCV -) Recipients: Is It Safe?
Ohio State University, Columbus, OH
*Purpose: Kidneys procured from HCV Ab+/NAT - are not routinely used due to concern for HCV transmission into recipients. However, there has been no report…2019 American Transplant Congress
Hepatitis C Treatment and Transplant Outcomes in Liver Transplant Recipients with Hepatitis C Positive Donors
University of Maryland Medical Center, Baltimore, MD
*Purpose: With direct-acting antivirals for hepatitis C virus (HCV), transplant centers have expanded the donor pool with positive short term outcomes with early HCV treatment.…2019 American Transplant Congress
Multicenter Experience Evaluating Outcomes of HCV-Seropositive Donors to HCV-Seronegative Recipients Liver Transplantation
*Purpose: Grafts from hepatitis C virus (HCV)-seropositive donors can now be considered for liver transplant (LT) due to the advent of direct-acting antiviral agents (DAA).…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 28
- Next Page »